Consensus Verastem, Inc.

Stocks

VSTM

US92337C2035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:08:49 2026-06-23 EDT			5-day change	1st Jan Change
4.295 ^USD	+1.06%		+6.61%	-44.62%

06-17	Verastem Inc Announces Positive Updated Safety and Efficacy Results from Ramp 205 Phase 1B 2A Trial of Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab Paclitaxel in First Line Mpdac	CI
06-16	Verastem Doses First Patient in Pancreatic Cancer Trial	DJ

Evolution of the Average Target: Verastem, Inc.

Evolution of the Target Price: Verastem, Inc.

Changes in Analyst Recommendations: Verastem, Inc.

d.4Ejx0FSsooyjNXFWmcnPYNnqSx9kkV4qRB35pcGOnGM.iwqck23a9_7seDsO_KH5UqqdPU0M6xwbD3O39bT7yhKhAaGUYZrj9ORGSQ~5f47decfc4644aa745da2538a0f4478e

Analysts' recommendations: Verastem, Inc.

05-14	Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Keeps Verastem Price Target to $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating	MT
01-08	RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk	MT
11-05	RBC Capital Adjusts Verastem Price Target to $14 From $13, Maintains Outperform Rating	MT
25-10-19	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma	CI
25-08-26	B. Riley Raises Price Target on Verastem to $16 From $13, Keeps Buy Rating	MT
25-08-15	Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
25-08-08	RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk	MT
25-06-25	RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk	MT
25-05-09	B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating	MT
25-05-09	Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating	MT
25-05-09	RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk	MT
25-04-28	B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating	MT
25-04-10	Jefferies Initiates Verastem at Buy With $15 Price Target	MT
25-04-08	Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating	MT
25-03-21	RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
25-01-31	B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating	MT
25-01-07	RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk	MT
24-12-31	BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating	MT
24-12-18	Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating	MT
24-09-30	Guggenheim Initiates Coverage on Verastem With Buy Rating, $13 Price Target	MT
24-08-09	RBC Adjusts Price Target on Verastem to $13 From $16, Maintains Outperform Rating	MT
24-07-29	Mizuho Adjusts Price Target on Verastem to $7 From $36 Following Model Update, Maintains Outperform Rating	MT
24-07-24	B. Riley Adjusts Verastem's PT to $7 From $21, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERASTEM, INC.					+276.47%
	ARGENX SE					+8.33%
	WUXI APPTEC CO., LTD.					+36.63%
	BIONTECH SE					+37.33%
	INSMED INCORPORATED					+99.84%
	WUXI BIOLOGICS (CAYMAN) INC.					+52.44%
	GENMAB A/S					+39.72%
	EXELIXIS, INC.					-4.58%
	PHARMAESSENTIA CORPORATION					-25.98%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+39.56%
	Average					+55.98%
	Weighted average by Cap.					+31.37%